Clinical Trials Logo

Endoscopy clinical trials

View clinical trials related to Endoscopy.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04719117 Enrolling by invitation - Clinical trials for Artificial Intelligence

Retrograde Cholangiopancreatography AI Assisted System Validation on Effectiveness and Safety

Start date: September 1, 2020
Phase:
Study type: Observational

In this study, the investigators proposed a prospective study about the effectiveness of artificial intelligence system for Retrograde cholangiopancreatography. The subjects would be include in an analyses groups. The AI-assisted system helps endoscopic physicians estimate the difficulty of Endoscopic retrograde cholangiopancreatography for choledocholithiasis and make recommendations based on guidelines and difficulty scores. The investigators used the stone removal times, success rate of stone extraction and Operating time to reflect the difficulty of the operation, and evaluated whether the results of the AI system were correct.

NCT ID: NCT04680858 Enrolling by invitation - Communication Clinical Trials

Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19

EndoCom
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Team work is highly challenged by the COVID-19 pandemic. Necessary protective equipment as FFP-mask and face shields impair communication significantly.Objective of the study is to evalaute the impact of digital enhanced telecommunication in endoscopic procedures.

NCT ID: NCT03940391 Enrolling by invitation - Endoscopy Clinical Trials

Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

This single-blind prospective study is aimed to investigate the effect of antihistamine as an adjunctive sedative for the patients with histories of severe paradoxical reaction to midazolam during sedative endoscopy. Participating patients are to receive antihistamine intravenously in addition to midazolam. The primary outcome is the reduction of paradoxical reaction in the antihistamine combination group. The secondary outcome is to compare sedation quality, performance quality, reduction of total midazolam dose will be analyzed between antihistamine combination and midazolam only group.